Zevra Therapeutics, Inc.
ZVRA
$12.24
-$0.44-3.43%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 2,103.59% | 235.04% | 178.88% | 139.40% | 103.96% |
| Total Depreciation and Amortization | -77.36% | -57.18% | -36.55% | -3.40% | 65.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 36.59% | -376.40% | -270.18% | -322.93% | -1,234.69% |
| Change in Net Operating Assets | 81.15% | 27.40% | -268.63% | -399.68% | -644.02% |
| Cash from Operations | 172.27% | 120.68% | 97.71% | 66.42% | 17.56% |
| Capital Expenditure | -148.40% | -678.79% | -- | -1,102.78% | -27.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 513.99% | 265.50% | 183.54% | -47.86% | -222.72% |
| Cash from Investing | 843.75% | 430.16% | 181.80% | 303.59% | 25.29% |
| Total Debt Issued | -- | -- | -- | -100.00% | -100.00% |
| Total Debt Repaid | -16,053.76% | -38.13% | 99.14% | 99.22% | 99.22% |
| Issuance of Common Stock | -70.13% | -70.04% | -81.51% | -85.27% | 777.42% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | 100.00% |
| Cash from Financing | -161.48% | -151.33% | -85.31% | -88.05% | 43.38% |
| Foreign Exchange rate Adjustments | -178.76% | 398.43% | -93.83% | 673.48% | -10.56% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,054.86% | 1,157.45% | 408.95% | -96.29% | 131.38% |